Evidence map›Paper›PMID 33903952›Full record

Trial reportAnnals of hematology2021

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).

Anna Hecht, Julia A Meyer, Johann-Christoph Jann, Katja Sockel, Aristoteles Giagounidis, Katharina S Götze, Anne Letsch, Detlef Haase, Richard F Schlenk, Torsten Haferlach and 16 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 16 institutions in 2 countries.

Anna HechtDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany. anna.hecht@medma.uni-heidelberg.de.
Julia A MeyerDepartment of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Johann-Christoph JannDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Katja SockelDepartment of Hematology, University Hospital Dresden, Dresden, Germany.
Aristoteles GiagounidisDepartment of Hematology, Oncology and Palliative Care, Marien Hospital Duesseldorf, Duesseldorf, Germany.
Katharina S GötzeDepartment of Internal Medicine, Technical University of Munich, Munich, Germany.
Anne LetschDepartment of Hematology and Oncology, Charité, Benjamin Franklin University, Berlin, Germany.
Detlef HaaseClinics of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.
Richard F SchlenkDepartment of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Philippe SchafhausenDepartment of Oncology, Hematology, BMT with section Pneumology, Hubertus Wald Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Gesine BugDepartment of Internal Medicine, University Hospital Frankfurt, Frankfurt, Germany.
Michael LübbertInternal Medicine, University Hospital Freiburg, Freiburg, Germany.
Felicitas TholDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Guntram BüscheHannover Medical School, Institute of Pathology, Hannover, Germany.
Esther SchulerDepartment for Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University, Duesseldorf, Germany.
Verena NowakDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Julia ObländerDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Stephanie FeyDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Nadine MüllerDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Georgia MetzgerothDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Ulrich GermingDepartment for Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University, Duesseldorf, Germany.
Florian NolteDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Mark ReinwaldBrandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
Daniel NowakDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Heidelberg University · DEUniversity Medical Centre Mannheim · DEMedizinische Hochschule Hannover · DEUniversity Hospital Heidelberg · DECharité - Universitätsmedizin Berlin · DEDüsseldorf University Hospital · DEHeinrich Heine University Düsseldorf · DEMarien Hospital Düsseldorf · DEMedizinische Hochschule Brandenburg Theodor Fontane · DEMunich Leukemia Laboratory (Germany) · DETechnical University of Munich · DEUniversity Cancer Center Hamburg · DEUniversity Hospital Carl Gustav Carus · DEUniversity Hospital Frankfurt · DEUniversity Medical Center Freiburg · DEUniversity of California, San Francisco · US

Funding

Deutsche Forschungsgemeinschaft NO817/5-2Deutsche Krebshilfe 70113953Dr. Rolf M. Schwiete Fund Project 20/2016H.W. & J. Hector Fund M83José Carreras Leukämie-Stiftung DJCLS H 03/01
6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) with isolated deletion of chromosome 5q (MDS del5q) is a distinct subtype of MDS with quite favorable prognosis and excellent response to treatment with lenalidomide. Still, a relevant percentage of patients do not respond to lenalidomide and even experience progression to acute myeloid leukemia (AML). In this study, we aimed to investigate whether global DNA methylation patterns could predict response to lenalidomide. Genome-wide DNA methylation analysis using Illumina 450k methylation arrays was performed on n=51 patients with MDS del5q who were uniformly treated with lenalidomide in a prospective multicenter trial of the German MDS study group. To study potential direct effects of lenalidomide on DNA methylation, 17 paired samples pre- and post-treatment were analyzed. Our results revealed no relevant effect of lenalidomide on methylation status. Furthermore, methylation patterns prior to therapy could not predict lenalidomide response. However, methylation clustering identified a group of patients with a trend towards inferior overall survival. These patients showed hypermethylation of several interesting target genes, including genes of relevant signaling pathways, potentially indicating the evaluation of novel therapeutic targets.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsChromosome DeletionChromosomes, Human, Pair 5DNA MethylationFemaleHumansLenalidomideMaleMiddle AgedMyelodysplastic SyndromesTreatment OutcomeAntineoplastic AgentsLenalidomideDeletion 5qDNA methylationLenalidomideMyelodysplastic syndromes

Identifiers

PMID33903952
PMCPMC8116243
OpenAlexW3157098080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.